Advancing Treatments
The process of developing new drugs begins in the laboratory where scientists probe the molecular machinery of a disease. At Lombardi, researchers are discovering key molecules that can be targeted to stop progression - or even cure - prostate cancer. They are also developing new treatments that re-sensitize a tumor to radiation or chemotherapeutics, and provide second and third line treatments when needed.
- AIB1 Integration of Hormonal and Growth Factor Signals ( Anna Riegel )
- AMP-activated Protein Kinase as a Molecular Regulator of Prostate Cancer Radiation Resistance ( Sean Collins )
- Contribution of hTERT in prostate cancer metastasis ( Partha Banerjee )
- Developing Selective HDAC Inhibitors ( Milton Brown / Anatoly Dritschilo / Mira Jung )
- Discovery of Novel Raf/Ras Protein Inhibitors ( Milton Brown / Anatoly Dritschilo / Usha Kasid )
- Inhibitors of Myosin Light Chain Phosphatase ( Milton Brown )
- Investigating Sodium Channel Blockers ( Milton Brown )
- Role of ErbB-2 and Pten in Prostate Cancer initiation and progression ( Christopher Albanese )
- Role of the PCPH gene in the development and invasiveness of prostate carcinoma ( Vicente Notario )
- Scatter factor protects prostate cancer cells against apoptosis ( Eliot Rosen )
- The p75 Neurotrophin Receptor Signaling Pathway as a Novel Therapeutic Target in Prostate Cancer ( Daniel Djakiew )
- Tumor suppressor signaling pathways in prostate cancer ( Albert J. Fornace, Jr. )
- Tumor/stromal interactions via growth factor signaling ( Anton Wellstein )